学习经历
2008.09-2013.06 北京大学/北京生命科学研究所,生物化学与分子生物学 (博士)
2003.09-2008.07 武汉大学医学院,临床医学(学士);武汉大学生命科学学院,生物科学(学士,双学位)
主要工作经历与任职情况
2022.07-至今 武汉大学泰康生命医学中心,PI
2019.11-至今 武汉大学生命科学学院,病毒学国家重点实验室,PI
2016.08-2019.09 美国南加州大学医学院分子微生物与免疫学系,博士后
2013.07-2016.08 北京生命科学研究所/默沙东研发(中国),联合博士后
主要社会兼职
中国研究型医院学会病毒肿瘤学专业委员会常任委员
国际乙肝基金会(HBF)新兴学者科学和医学顾问委员会委员(E-SMAB)
湖北省微生物学会病毒学专业委员会 委员
Nature, Science Advances, Cell Reports, hLife, Viruses等期刊的审稿人
获奖及荣誉
吴瑞奖学金-吴瑞基金会 2013
湖北省高层次人才项目 2020
主持课题项目
2021-2024年 国自然面上项目 主持
2023-2026年 国自然面上项目 主持
2024-2026年 国自然优秀青年科学基金 主持
2023-2026年 国家重点研发计划 参与
2024-2027年 国家重点研发计划 参与
实验室研究生部分获奖与项目
国家奖学金 4人次
武汉大学“研究生学术创新奖”特等奖 1人次
武汉大学雷军卓越奖学金 1人次
武汉大学十大学术之星 1人次
国家自然科学基金青年学生基础研究项目(博士研究生) 1人次
吉凯病毒学青年创新奖 3人次
主要研究领域与成果简介
长期从事病毒受体与入侵机制相关研究。以冠状病毒、乙肝病毒等多种与公共卫生与传染病防控有关的重要病原为研究对象,致力于寻找、鉴定、设计病毒受体, 揭示病毒感染、传播与致病的分子机制,建立新型感染评价模型与感染抵抗模型,开发病毒预防与治疗新策略。
代表性研究成果包括:
(1) 成功鉴定HBV受体NTCP,被誉为领域内里程碑式的工作(elife, 2012 等);成功鉴定出HPV受体结合多肽L2N(mbio, 2019);
(2) 系统分析了SARS簇冠状病毒刺突蛋白与多物种ACE2受体相互作用的机制,揭示了该亚属病毒在适应ACE2过程中三条不同的进化路径(Nature Ecol Evol, 2021; Nature Commun, 2023);
(3) 陆续鉴定出NeoCoV,MOW15-22, HKU5和HKU25等蝙蝠MERS簇冠状病毒的受体,揭示了第三、第四和第五种新的ACE2识别模式,刷新了领域对该亚属病毒受体使用的认知(Nature, 2022; Cell, 2025a; Cell, 2025b; Cell, 2025c; 等);
(4) 首次提出了“定制化病毒受体”的概念,为受体“智造”与抗病毒药物研发提供新思路(Nature, 2024)。
Prof. Yan has long been engaged in research on viral receptors and entry mechanisms, focusing on pathogens of significant public health concern, such as coronaviruses and hepatitis B virus (HBV). Our goal is to identify, design, and engineer viral receptors to elucidate the molecular mechanisms underlying viral infection, transmission, and pathogenesis. We aim to establish novel infection evaluation models and models that confer resistance to infection, as well as to create innovative strategies for viral prevention and treatment.
Representative research achievements include:
(1) Landmark identification of NTCP as the HBV receptor (eLife, 2012), and discovery of HPV receptor-binding peptide L2N (mBio, 2019);
(2) Comprehensive analysis of SARS-related coronavirus spike protein interactions with ACE2 orthologs from various species, revealing three distinct evolutionary pathways in ACE2 adaptation (Nature Ecol Evol, 2021; Nature Commun, 2023);
(3) Identification of receptors for bat-borne MERS-like coronaviruses (NeoCoV, MOW15-22, HKU5, and HKU25), unveiling the third to fifth novel ACE2 recognition modes, which reshape our understanding of receptor usage of merbecovirus subgenus (Nature, 2022; Cell, 2025a; Cell, 2025b; Cell, 2025c; etc.);
(4) Pioneering the concept of "customized viral receptors", which provides new paradigms for intelligent receptor engineering and facilitates the development of novel antiviral strategies (Nature, 2024).
代表性论文(#并列第一作者,*通讯作者)
1. Cheng-Bao Ma#, Chen Liu#, Young-Jun Park#, Jingjing Tang#, Jing Chen#, Qing Xiong, Jimin Lee, Cameron Stewart, Daniel Asarnow, Jack Brown, M Alejandra Tortorici, Xiao Yang, Ye-Hui Sun, Yuan-Mei Chen, Xiao Yu, Jun-Yu Si, Peng Liu, Fei Tong, Mei-Ling Huang, Jing Li, Zheng-Li Shi*, Zengqin Deng*, David Veesler*, Huan Yan*. Multiple independent acquisitions of ACE2 usage in MERS-related coronaviruses. Cell. 2025 Feb 4:S0092-8674(24)01474-0.
2. Peng Liu# , Mei-Ling Huang# , Hua Guo# , Matthew McCallum# , Jun-Yu Siˈ Yuan-Mei Chenˈ Chun-Li Wang , Xiao Yu , Lu-Lu Shi , Qing Xiong , Cheng-Bao Ma , John E. Bowen, Fei Tong, Chen Liu, Ye-hui Sun, Xiao Yangˈ Jing Chen, Ming Guo, Jing Li, Davide Corti, David Veesler*, Zheng-Li Shi*, Huan Yan*. Design of customized coronavirus receptors. Nature. 2024 Nov; 635(8040):978-986.
3. Qing Xiong#, Lei Cao#, Chengbao Ma#, M. Alejandra Tortorici#, Chen Liu, Junyu Si, Peng Liu, Mengxue Gu1, Alexandra C. Walls, Chunli Wang, Lulu Shi, Fei Tong, Meiling Huang, Jing Li, Chufeng Zhao, Chao Shen, Yu Chen, Huabin Zhao, Ke Lan, Davide Corti, David Veesler*, Xiangxi Wang*, Huan Yan*. Close relatives of MERS-CoV in bats use ACE2 as their functional receptors. Nature. 2022 Dec;612(7941):748-757.
4. Young-Jun Park#, Chen Liu#, Jimin Lee, Jack T Brown, Cheng-Bao Ma, Peng Liu, Risako Gen, Qing Xiong, Samantha K Zepeda, Cameron Stewart, Amin Addetia, Caroline J Craig, M Alejandra Tortorici, Abeer N Alshukairi, Tyler N Starr, Huan Yan*, David Veesler*, Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses. Cell. 2025 Feb 3:S0092-8674(24)01475-2
5. Jing Chen#, Wei Zhang#, Yang Li#, Chen Liu#, Tianyi Dong, Huiyu Chen, Chunguang Wu, Jia Su, Bei Li, Wei Zhang, Ben Hu, Jingkun Jia, Cheng-Bao Ma, Yan Zhu, Xiangyang He, Ang Li, Kaiyi Pan, Haofeng Lin, Zishuo Guo, Cong Li, Libiao Zhang*, Huan Yan*, Peng Zhou*, Wei Peng*, Zheng-Li Shi*. Bat-infecting merbecovirus HKU5-CoV lineage 2 can use human ACE2 as a cell entry receptor. Cell. 2025 Feb 12:S0092-8674(25)00144-8.
6. Junyu Si# , Yuanmei Chen#, Yehui Sun# , Mengxue Gu, Meiling Huang, Lulu Shi, Xiao Yu, Xiao Yang, Qing Xiong, Chenbao Ma, Peng Liu, Zheng-Li Shi, Huan Yan*. Sarbecovirus RBD indels and specific residues dictating multi-species ACE2 adaptiveness. Nat Commun. 2024 Oct 14;15(1):8869.
7. Chengbao Ma#, Chen Liu#, Qing Xiong#, Mengxue Gu, Lulu Shi, Chunli Wang, Junyu Si, Fei Tong, Peng Liu, Meiling Huang, Huan Yan. Broad host tropism of ACE2-using MERS-related coronaviruses and determinants restricting viral recognition. Cell Discovery. 2023 Jun 15;9(1):57.
8. Qianyun Liu#,Haiyan Zhao#,Zhiqiang Li#,Zhen Zhang#,Rui Huang#,Mengxue Gu,Ke Zhuang,Qing Xiong,Xianying Chen,Weiyi Yu, Shengnan Qian, Yuzhen Zhang, Xue Tan, Muyi Zhang, Feiyang Yu, Ming Guo, Zhixiang Huang, Xin Wang, Wenjie Xiang, Bihao Wu, Fanghua Mei, Kun Cai, Limin Zhou, Li Zhou, Ying Wu*, Huan Yan*, Sheng Cao*, Ke Lan*, Yu Chen*. Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge. Signal Transduct Target Ther. 2023 Sep 14;8:347.
9. Qianyun Liu#, Qing Xiong#, Fanghua Mei#, Chengbao Ma, Zhen Zhang, Bing Hu, Junqiang Xu, Yongzhong Jiang, Faxian Zhan, Suhua Zhou, Li Tao, Xianying Chen, Ming Guo, Xin Wang, Yaohui Fang, Shu Shen, Yingle Liu, Fang Liu, Li Zhou, Ke Xu, Changwen Ke, Fei Deng, Kun Cai*, Huan Yan*, Yu Chen*, Ke Lan*. Antibody neutralization to SARS-CoV-2 and variants after one year in Wuhan, China. The Innovation. 2022 Jan 25;3(1):100181.
10. Chengbao Ma#, Xianying Chen#, Fanghua Mei#, Qing Xiong, Qianyun Liu, Lianghui Dong, Chen Liu, Wenjing Zou, Faxian Zhan, Bing Hu, Yingle Liu, Fang Liu, Li Zhou, Junqiang Xu, Yongzhong Jiang, Ke Xu, Kun Cai*, Yu Chen*, Huan Yan*,Ke Lan*. Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents. Emerg Microbes Infect. 2022 Dec;11(1):567-572.
11. Huan Yan#, Hengwu Jiao#, Qianyun Liu, Zhen Zhang, Qing Xiong, Bing-Jun Wang, Xin Wang, Ming Guo, Lin-Fa Wang, Ke Lan*, Yu Chen* & Huabin Zhao*. ACE2 receptor usage reveals variation in susceptibility to SARS-CoV and SARS-CoV-2 infection among bat species. Nature Ecol Evol 2021 May;5(5):600-608.
成立实验室前:
1. Huan Yan#, Guocai Zhong# , Guangwei Xu, Wenhui He, Zhiyi Jing, Zhenchao Gao, Yi Huang, Yonghe Qi, Bo Peng, Haimin Wang, Liran Fu, Mei Song, Pan Chen, Wenqing Gao, Bijie Ren, Yinyan Sun, Tao Cai, Xiaofeng Feng, Jianhua Sui, Wenhui Li*. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife. 2012; 1: e00049.
2. Huan Yan, Suan-Sin Foo, Weiqiang Chen, Ji-Seung Yoo, Woo-Jin Shin, Christine Wu, Jae U. Jung*. Efficient inhibition of Human Papillomavirus infection by L2 minor capsid-derived lipopeptide. mBio. 2019 Aug 6;10(4):e01834-19.
3. Huan Yan#, Bo Peng#, Yang Liu, Guangwei Xu, Wenhui He, Bijie Ren, Zhiyi Jing, Jianhua Sui, Wenhui Li. Viral Entry of Hepatitis B and D Viruses and Bile Salts Transportation Share Common Molecular Determinants on Sodium Taurocholate Cotransporting Polypeptide. J Virol. 2014 Mar;88(6):3273-84.
4. Huan Yan#, Bo Peng#, Wenhui He, Guocai Zhong, Yonghe Qi, Bijie Ren, Zhenchao Gao, Zhiyi Jing, Mei Song, Guangwei Xu, Jianhua Sui, Wenhui Li*.Molecular determinants of hepatitis B and d virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol., 2013 Jul;87(14):7977-91.
5. Yang Liu#, Lei Zhang#, Huan Yan#, Zhiqiang Wang, Guoliang Sun, Xiao Song, Zhongmin Zhou, Bo Peng, Liwei Yan, Qingcui Wu, Wenhui Li*, and Xiangbing Qi*. Design of Dimeric Bile Acid Derivatives as Potent and Selective Human NTCP Inhibitors. J. Med. Chem., 2021 May 13;64(9):5973-6007.
6. Shixian Lin#, Huan Yan#, Lin Li, Maiyun Yang, Bo Peng, She Chen, Wenhui Li*, Peng R Chen*. Site-specific Engineering of Chemical Functionalities on the Surface of Live Hepatitis D Virus. Angew. Chem. Int. Ed., 2013 Dec;52(52), 13970-4.
综述:
1. Huan Yan, Wenhui Li. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus. Dig Dis. 2015 May; 33(3):388-96.
2. Huan Yan, Yang Liu, Jianhua Sui, Wenhui Li. NTCP opens the door for hepatitis B virus infection. Antiviral Res. 2015 Sep;121:24-30.
3. Huan Yan, Chunli Wang, Key Factors for “Fishing” NTCP as a Functional Receptor for HBV and HDV. Viruses. 2023; 15(2), 512
招生招聘
欢迎对病毒学研究感兴趣的本科生、研究生、博士生或博士后加入我们的团队! 有意向加入者请将简历发送至huanyan@whu.edu.cn。